fexapotide: Clinical Trials

7 trials of fexapotide, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 1 terminated. 5 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 35Completed 4, Terminated 1
Phase 22Completed 2

Follow fexapotide: new trials by email Literature Review of fexapotide trials Research Report on fexapotide

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of a Single TRUS-guided Intraprostatic Injection of NX-1207 in Patients With LUTS Due to BPH
NX-1207, Tamsulosin - Lower Urinary Tract Symptoms
Phase 3TerminatedRECORDATI GROUP1042013-09-012022-05-26
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
NX-1207 - Benign Prostatic Hyperplasia, BPH
Phase 3CompletedNymox Corporation1602013-04-012017-03-10
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
NX-1207 2.5 mg, NX-1207 15 mg - Prostate Cancer
Phase 2CompletedNymox Corporation1412012-02-212017-03-10
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
NX-1207 - Benign Prostatic Hyperplasia
Phase 3CompletedNymox Corporation1922011-09-012014-04-30
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018
NX-1207, Placebo - Benign Prostatic Hyperplasia (BPH)
Phase 3CompletedNymox Corporation5002009-05-012017-03-10
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
NX-1207, Placebo - Benign Prostatic Hyperplasia
Phase 3CompletedNymox Corporation5002009-04-012014-04-30
Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)
2.5 mg NX-1207, 0.125 mg NX-1207, finasteride - Benign Prostatic Hyperplasia (BPH), Enlarged Prostate
Phase 2CompletedNymox Corporation852007-05-012012-06-14

Conditions studied

Prostatic Hyperplasia (5)  ·  Lower Urinary Tract Symptoms (3)  ·  Urinary Bladder Neck Obstruction (2)  ·  Prostatic Neoplasms (1)

Sponsors

Nymox Corporation (6)  ·  RECORDATI GROUP (1)

Countries

United States (6)  ·  Germany (1)  ·  Italy (1)  ·  Poland (1)  ·  Spain (1)  ·  United Kingdom (1)